Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 181 to 190 of 797

TitleReference numberPublishedLast updated
Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal)TA846
Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal)TA847
Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal)TA844
Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal)TA843
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA841
Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal)TA842
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal)TA839
Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal)TA840
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal)TA838
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanomaTA837

Results per page

  1. 10
  2. 25
  3. 50
  4. All